Moderna announces first participant dosed in phase 1 study of its hiv trimer mrna vaccine

Cambridge, ma / accesswire / march 14, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (hiv) trimer mrna vaccine (mrna-1574). "developing a vaccine regimen that induces sustained protective levels of hiv neutralizing antibodies in humans has been difficult to achieve.
MRNA Ratings Summary
MRNA Quant Ranking